CMS’s CY 2027 Medicare Advantage rates signal mounting cost pressure, setting the stage for tighter benefits, tougher contracting, and heightened access scrutiny in the months ahead.
William Fleming, PharmD
Advertisement
Articles by William Fleming, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
How China Turned US Trade Compliance Into a Supply Chain Risk
2
Roundtable: The State of Hub Services in 2026
3
Why Market Access Strategy Can No Longer Wait Until Launch
4
GEODIS Thermal Covers Mark Step Toward Sustainable Pharma Airfreight Packaging
5